4.7 Article

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease

Journal

BRAIN
Volume 140, Issue -, Pages 3286-3300

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/awx243

Keywords

Alzheimer's disease; tau; amyloid; atrophy; cognitive impairment

Funding

  1. Fondation pour la Recherche Medicale
  2. National Institute on Aging [R01-AG045611, R01-AG034570, P50-AG023501, P01-AG019724, U01-AG052943]
  3. National Institute of Neurological Disorders and Stroke [R01-NS050915, K24-DC015544]
  4. Tau Consortium
  5. State of California Department of Health Services Alzheimer's Disease Research Centre of California grant [04-33516]
  6. John Douglas French Alzheimer's Foundation

Ask authors/readers for more resources

Neuropathological and in vivo studies have revealed a tight relationship between tau pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau pathology is also intimately associated with neurodegeneration and amyloid pathology. The aim of the present study was therefore to assess whether grey matter atrophy and amyloid pathology contribute to the relationship between tau pathology, as measured with F-18-AV-1451-PET imaging, and cognitive deficits in Alzheimer's disease. We included 40 amyloid-positive patients meeting criteria for mild cognitive impairment due to Alzheimer's disease (n = 5) or probable Alzheimer's disease dementia (n = 35). Twelve patients additionally fulfilled the diagnostic criteria for posterior cortical atrophy and eight for logopenic variant primary progressive aphasia. All participants underwent 3 T magnetic resonance imaging, amyloid (C-11-PiB) positron emission tomography and tau (F-18-AV-1451) positron emission tomography, and episodic and semantic memory, language, executive and visuospatial functions assessment. Raw cognitive scores were converted to age-adjusted Z-scores (W-scores) and averaged to compute composite scores for each cognitive domain. Independent regressions were performed between F-18-AV-1451 binding and each cognitive domain, and we used the Biological Parametric Mapping toolbox to further control for local grey matter volumes, C-11-PiB uptake, or both. Partial correlations and causal mediation analyses (mediation R package) were then performed in brain regions showing an association between cognition and both F-18-AV-1451 uptake and grey matter volume. Our results showed that decreased cognitive performance in each domain was related to increased F-18-AV-1451 binding in specific brain regions conforming to established brain-behaviour relationships (i.e. episodic memory: medial temporal lobe and angular gyrus; semantic memory: left anterior temporal regions; language: left posterior superior temporal lobe and supramarginal gyrus; executive functions: bilateral frontoparietal regions; visuospatial functions: right more than left occipitotemporal regions). This pattern of regional associations remained essentially unchanged-although less spatially extended-when grey matter volume or C-11-PiB uptake maps were added as covariates. Mediation analyses revealed both direct and grey matter-mediated effects of F-18-AV-1451 uptake on cognitive performance. Together, these results show that tau pathology is related in a region-specific manner to cognitive impairment in Alzheimer's disease. These regional relationships are weakly related to amyloid burden, but are in part mediated by grey matter volumes. This suggests that tau pathology may lead to cognitive deficits through a variety of mechanisms, including, but not restricted to, grey matter loss. These results might have implications for future therapeutic trials targeting tau pathology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available